AKT1 and colonic neoplasm: The drug-containing serum of the Jianshuang Cancer Control Formula inhibited human colon cancer HCT116 cell proliferation [114], which was associated with the regulation of the ANP32A/p38/AKT signaling pathway by inhibiting ANP32A expression, increasing p38 phosphorylation, and inhibiting AKT phosphorylation [115].